Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

November 30, 2007

Study Completion Date

March 12, 2009

Conditions

Malignant Melanoma

Interventions

BIOLOGICAL

8 HLA-A2-restricted peptides and Montanide ISA51

BIOLOGICAL

8 HLA-A2-restricted peptides and CpG 7909

Trial Locations (2)

Clinique Universitaires St-Luc, Brussels

Ludwig Institute for Cancer Research, Brussels